Searchable abstracts of presentations at key conferences in endocrinology

ea0022p645 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term treatment of acromegaly with pasireotide (SOM230): results from a Phase II extension study

Farrall Andrew , Ruffin Matthieu , Wetli-Hermosillo Karina , Petersenn Stephan

Introduction: Pasireotide (SOM230) is a multi-receptor targeted somatostatin analogue with high binding affinity for sst1,2,3 and sst5. In a Phase II study of pasireotide in patients with active acromegaly, 27% achieved biochemical control after 1 month of octreotide s.c. followed by 3 months of pasireotide, and pituitary tumor volume decreased by >20% in 39% of patients. Results from the study’s extension phase are presented.<p class="abstex...

ea0020p31 | Adrenal | ECE2009

Confounding variables for plasma metanephrines and normetanephrines may influence the diagnosis of pheochromocytomas

Deutschbein Timo , Jager Andrea , Mann Klaus , Petersenn Stephan

Introduction: Measurements of plasma metanephrines (META) and normetanephrines (NOR) have been advocated as first-line tests for the diagnosis of pheochromocytoma. This study assessed the impact of several potential confounders, which may influence the correct diagnosis.Methods: Eight healthy males (age 26.8±1.7; BMI 23.1±0.8) were tested on 6 separate days. Tests were performed in supine rest with blood sampling via i.v. canullas at 0900 h fol...

ea0016oc1.4 | Neuroendocrinology and pituitary | ECE2008

Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a phase II extension study

Farrall Andrew J , Glusman Joan E , Ruffin Matthieu , Petersenn Stephan

Introduction: In a recent 16-week Phase II study in patients with de novo, persistent or recurrent acromegaly, pasireotide effectively controlled GH and/or IGF-I levels in 56% of patients, and reduced tumor volume by >20% in 39% of patients. We present preliminary 6-month results from the ongoing extension phase of this study.Methods: This extension study enrolled patients who achieved biochemical control (GH ≤2.5 μg/l and normalize...

ea0016p595 | Paediatric endocrinology | ECE2008

Day profiles of salivary 17-hydroxyprogesterone for the control of glucocorticoid therapy in adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Deutschbein Timo , Unger Nicole , Hauffa Berthold , Mann Klaus , Petersenn Stephan

Introduction: Optimizing glucocorticoid (GC) therapy in patients with congenital adrenal hyperplasia (CAH) remains a challenge. While overdosing may result in Cushing’s syndrome, underdosing is associated with female virilization and adrenal insufficiency. This study evaluated day-profiling of salivary 17-hydroxyprogesterone (17OHP) for the biochemical control of adolescents with CAH due to 21-hydroxylase deficiency.Methods: Twelve patients (4 males...

ea0014p565 | (1) | ECE2007

The effects of pasireotide (SOM230) on glucose metabolism and growth hormone (GH) nadir during oral glucose tolerance test (OGTT) in 12 patients with acromegaly from a Phase II study

Petersenn Stephan , Glusman Joan , Unger Nicole , Mann Klaus

Introduction: Pasireotide (SOM230) is a novel multi-ligand somatostatin analogue with high binding affinity for four of the five somatostatin receptor subtypes (sst1,2,3 and sst5). A randomized study of 59 patients showed that pasireotide effectively controls GH and IGF-I levels in patients with acromegaly and reduces pituitary tumor size. The impact of pasireotide on GH levels during glucose suppression and glucose metabolism in 12 patients enrolled in t...

ea0063p731 | Pituitary and Neuroendocrinology 2 | ECE2019

Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study

Giustina Andrea , Bronstein Marcello , Chanson Philippe , Petersenn Stephan , Casanueva Felipe , Sert Caroline , Houchard Aude , Melmed Shlomo

Background: The SAGIT® instrument, designed to assist clinicians in staging and managing acromegaly, is undergoing validation. A descriptive analysis of SAGIT Validation study baseline data revealed discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly.Objective: To describe the baseline characteristics of patients in the SAGIT® valida...

ea0049oc12.2 | Pituitary Clinical | ECE2017

Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey

McCormack Ann , Dekkers Olaf M , Petersenn Stephan , Popovic Vera , Trouillas Jacqueline , Raverot Gerald , Burman Pia

Objective: To collect clinical and treatment outcome data in a large patient cohort, and specifically to report experience with temozolomide (TMZ).Design: Cohort study based on an electronic survey open for participation to ESE members Dec 2015-Nov 2016.Results: Reports on 167 patients, 40 pituitary carcinomas, and 127 aggressive pituitary tumours were obtained. Median age at diagnosis was 43 (range 4–79) years. 59% of tumours...

ea0049gp191 | Pituitary &amp; endocrine Tumours | ECE2017

GH and IGF-1 levels at 12 weeks predict long-term responses to lanreotide Autogel in treatment-naïve acromegalic patients: post-hoc analyses from the PRIMARYS study

Caron Philippe , Petersenn Stephan , Houchard Aude , Sert Caroline , Bevan John S

Background: In PRIMARYS, lanreotide Autogel (LAN) 120 mg/28 days reduced tumour volume (TV), and GH/IGF-1 levels in patients with GH-secreting macroadenomas. In post-hoc analyses, we investigated predictive factors for treatment responses.Methods: PRIMARYS, a 48-week, international, open-label study, involved 90 treatment-naïve patients with GH-secreting macroadenomas receiving LAN. Factors predictive for hormonal control (HC; GH ≤2.5...

ea0041gp153 | Pituitary - Clinical | ECE2016

Once-monthly injection of pasireotide LAR reduces urinary free cortisol (UFC) levels in patients with Cushing’s disease: Results from a randomised, multicentre, phase III trial

Newell-Price John , Petersenn Stephan , Biller Beverly M K , Roughton Michael , Ravichandran Shoba , Lacroix Andre

Background: Twice-daily formulation of pasireotide, a pituitary-directed therapy, is approved for treatment of Cushing’s disease. Here we present data from a phase III study designed to evaluate the more convenient once-monthly long-acting release (LAR) formulation of pasireotide (approved for acromegaly) in patients with Cushing’s disease.Methods: Patients with persistent, recurrent, or de novo Cushing’s disease (not candidates for surger...

ea0041gp160 | Pituitary - Clinical (1) | ECE2016

Anthropometric factors have significant influence on the outcome of the GHRH-arginine test – establishment of normative data

Deutschbein Timo , Bidlingmaier Martin , Schopohl Jochen , Strasburger Christian J , Petersenn Stephan

Background: Adult GH deficiency (GHD) is diagnosed by provocative testing of GH secretion. To improve diagnostic accuracy of GHRH plus arginine (GARG) testing, we evaluated the influence of age, BMI, and sex. Furthermore, we aimed to established normative data for an automatic immunoassay specifically measuring 22kD human GH.Methods: Eighty-seven patients with hypothalamic-pituitary disease and 200 healthy controls were enrolled. Controls were prospectiv...